Piper Sandler downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight with an unchanged price target of $10 following Roche’s announced acquisition for $9 per share in cash and $4 per share contingent rights value.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX:
- Poseida Therapeutics (NASDAQ:PSTX) Stock Skyrockets on News of Roche Holdings Acquisition
- Trump threatens tariffs, Zoom reports Q3 beat: Morning Buzz
- Poseida Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Poseida downgraded to Market Perform from Outperform at William Blair
- Poseida Therapeutics downgraded to Neutral from Buy at BTIG